“Retinitis Pigmentosa Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Retinitis Pigmentosa market. A detailed picture of the Retinitis Pigmentosa pipeline landscape is provided, which includes the disease overview and Retinitis Pigmentosa treatment guidelines.
Retinitis pigmentosa is a heterogeneous, progressive disease that leads to worsening of the vision with time.
Although, there is a significant variation in the age of onset, progression rate, the involvement of rod, and cone, retinal cells deterioration, however; the clinical manifestations that are kept in mind while diagnosing are night blindness, progressive loss of peripheral vision and subsequent loss of central vision.
The assessment part of the report embraces in-depth Retinitis Pigmentosa commercial assessment and clinical assessment of the Retinitis Pigmentosa pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Retinitis Pigmentosa collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Retinitis Pigmentosa Market
Present available options and approaches in the Retinitis pigmentosa market are limited. Hence, a number of clinical trials are underway, and a lot of novel therapies are poised to enter the Retinitis pigmentosa therapy market.
Several pharma and biotech companies including HORA-RPE65 (Horama), AAV8-RPGR (Nightstar Therapeutics), jCell (jCyte), Renexus (NT-501; Neurotech Pharmaceuticals), and hRPC (ReNeuron Limited) are expected to enter into Retinitis pigmentosa market in the coming decade.
The robust pipeline is anticipated to bring a significant shift in the Retinitis pigmentosa market in the 7MM. Moreover, the US is expected to grab the major chunk of Retinitis pigmentosa market share as compared to other members of 7MM.
The Retinitis Pigmentosa market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Retinitis Pigmentosa market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
According to DelveInsight, Retinitis Pigmentosa 7MM market is expected to change in the study period 2017–2030.
AAV8-RPGR/BIIB112: Nightstar Therapeutics/Biogen
Cenegermin: Dompé Farmaceutici
hRPC Cells: ReNeuron
UshStat: Sanofi (Terminated)
Scope of the report
- The Retinitis Pigmentosa report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Retinitis Pigmentosa across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Retinitis Pigmentosa therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Retinitis Pigmentosa research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Retinitis Pigmentosa.
Table of Contents
1. Report Introduction
2. Retinitis Pigmentosa
3. Retinitis Pigmentosa Current Treatment Patterns
4. Retinitis Pigmentosa – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Retinitis Pigmentosa Late Stage Products (Phase-III)
7. Retinitis Pigmentosa Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinitis Pigmentosa Discontinued Products
13. Retinitis Pigmentosa Product Profiles
14. Retinitis Pigmentosa Key Companies
15. Retinitis Pigmentosa Key Products
16. Dormant and Discontinued Products
17. Retinitis Pigmentosa Unmet Needs
18. Retinitis Pigmentosa Future Perspectives
19. Retinitis Pigmentosa Analyst Review
21. Report Methodology
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States